A5078402071- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
Chang Gung Memorial Hospital
2022-2024
Chang Gung University
2022-2024
Background and Aims: Long-term nucleos(t)ide analog (Nuc) treatment can reduce HCC in patients with HBV-related liver cirrhosis (HBV-LC). Earlier small cohort studies showed a comparable 5-year incidence of HBeAg-negative HBV-LC who stopped those continued Nuc therapy. This study aimed to validate these findings using large 10-year follow-up. Approach Results: From 2 centers, 494 (finite group) 593 (continuous therapy were recruited. HCC, HBsAg loss, liver-related mortality/transplantation,...
Background: Hepatocellular carcinoma (HCC) remains a significant concern for patients with chronic hepatitis C (HCV), even after achieving sustained virological response (SVR) direct-acting antivirals (DAAs) or interferon (IFN)-based therapies. This study compared the risk of HCC in HCV who achieved SVR through DAA versus IFN regimens. Methods: A retrospective analysis was conducted on 4806 patients, without coinfection nor prior history, treated at Chang Gung Memorial Hospital, Taiwan (DAA:...
Introduction: High sustained virological response (SVR) rate (>95%) and liver stiffness regression can be achieved with direct acting antivirals treatment (DAA) in patients chronic hepatitis C virus (CHC) infection. Reactivation of B (HBV) was reported during DAA co-infected HBV, although its impact on remains unknown. This study aims to investigate whether the (LSM) is different between HBV/HCV mono-HCV-infected patients. Materials Methods: CHC with/without HBV co-infection who received...